Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

4 Mar 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40133140
DOI: 10.1016/j.clml.2025.02.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisPMID 40133140Read ↗

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Semantic proximity Read ↗

Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.Semantic proximity Read ↗

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosisSemantic proximity Read ↗

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaSemantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.Semantic proximity Read ↗

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Semantic proximity Read ↗

Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.Semantic proximity Read ↗

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.